By: Benzinga
UPDATE: Jefferies Raises PT to $40 on Aegerion Pharmaceuticals on Strong Juxtapid Start
Jefferies maintained Aegerion Pharmaceuticals (NASDAQ: AEGR ) with a Buy rating and raised the price target from $29.00 to $40.00. Jefferies commented, "Wider 4Q12 loss of $22M on higher OpEx (vs. our estimate). To date 85 NRx written for Juxtapid (translating into $2M in sales once shipped, ~3-4 months following
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here